Insights

PA's life sciences consultants, recruited from senior positions in the pharmaceutical and healthcare industry, represent many years of experience, which they regularly distill into insightful and practical published advice. The following selection indicates the both the breadth of experience and depths of specialist advice they can offer. 

	Links to drug anti-counterfeiting information in the pharmaceutical industry
	Authentication at the point of dispensing - notes from Inaugural Stakeholder Meeting, 8 December 2003
	PA article on success factors for small biotech companies
	PA's ARBITER approach to better decision-making in Discovery
	PA's comment on US House of Representatives vote on drug imports
	PA's reaction to FDA announcement on drug counterfeiting
	PA's solution to product authentication
	Using e-business concepts as a vehicle for R&D cost containment
	R&D: the 'Atlantic-Pacific divide'

Impacts magazine
Bringing new drugs to market...at last! PA's research based upon 75 New Chemical Entities (NCEs) shows that performance in  this critical area is inconsistent.  Only 30 of the 75 product launches surveyed were available on the market within a month of approval
Click here to order a copy

See also:

The PA article published in the Wall Street Journal: 'How Biotech can avoid frankenfood syndrome'